OP0017BCMA CD19 COMPOUND CHIMERIC ANTIGEN RECEPTOR T CELLS (cCAR) PROVIDES COMPLETE HUMORAL RESET, ELIMINATES ALL ELEVATED AUTOANTIBODIES, IMPROVES SYMPTOMS AND RENAL FUNCTION IN LUPUS NEPHRITIS (LN) PATIENTSBackground: Lupus nephritis (LN) is a severe renal manifestation of systemic lupus ...
However, plasma cells were spared in the treatment of lupus with single target CD19 CAR T cells. Additionally, peripheral circulating anti-DNA IgG and IgM autoantibodies remain elevated or increased in treated mice. Here we present the efficacy of BCMA-CD19 compound CAR (cCAR), which target ...
BCMA-directed autologous chimeric antigen receptor T (CAR-T) cells have shown excellent clinical efficacy in relapsed or refractory multiple myeloma (RRMM), however, the current preparation process for autologous CAR-T cells is complicated and costly. Moreover, the upregulation of CD47 expression ha...
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth Article Open access 19 January 2024 Introduction Multiple myeloma (MM) is the second-most common hematologic malignancy, causing 98,437 deaths globally in 2016, with an estimated 32,110 new diagnoses in the US in 20191,2. In ...
BCMA-specific chimeric antigen receptor-T cells (CAR-Ts) have exhibited remarkable efficacy in refractory or relapsed multiple myeloma (RRMM); however, primary resistance and relapse exist with single-target immunotherapy. Bispecific CARs are proposed to
Journal of Translational Medicine (2022) 20:124 https://doi.org/10.1186/s12967-022-03326-6 Journal of Translational Medicine RESEARCH Open Access Two for one: targeting BCMA and CD19 in B‑cell malignancies with off‑the‑shelf dual‑CAR NK‑92 cells Gils Roex1 , ...
BCMA-GFP-Hela and CD47-GFP-Hela cells were prepared through lentivirus infection. pcDNA3.1 vector (cat# V79020, Invitrogen) was used for eukaryotic expression of the recombinant proteins, pMECS vector was used to construct phage library, LentiGuide-Puro (cat# 52963) and pSLCAR-CD19-BBz (cat...
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial Article Open access 20 April 2024 CAR T cell therapies for patients with multiple myeloma Article 25 September 2020 CAR-T cell therapy in Multiple Myeloma: current status and...
P-BCMA-101, which is in phase 2 trials, is an autologous product, recycling a patient's own cells; P-BCMA-ALLO1 is an allogeneic version, in which gene editing has been used to knock out cross-reactive func- tions; and dual CAR T (BCMA/CD19) is a further adaptation of the ...
The BCMA antibody described herein is useful for any therapeutic in which it is desirable to target BCMA, such as adoptive cell transfer (ACT), bispecific T-cell engagers (BiTEs), and nanoparticles. In one embodiment, the disclosure provides a chimeric antigen receptor (CAR) comprising an anti...